BeOne Medicines (BEIGF) Change in Receivables (2017 - 2026)

BeOne Medicines (BEIGF) has reported Change in Receivables for 10 consecutive years, with $117.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables rose 183.3% year-over-year to $117.6 million in Q2 2026; TTM through Jun 2026 was $284.5 million, a 24.26% increase from a year earlier, with the FY2025 full-year figure at $165.0 million, down 49.93% from the prior year.
• Change in Receivables was $117.6 million for Q2 2026 at BeOne Medicines, up from $75.3 million in the prior quarter.
• Over five years, Change in Receivables peaked at $136.5 million in Q1 2023 and troughed at -$292.6 million in Q1 2022.
• A 5-year average of $31.7 million and a median of $36.7 million in 2025 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables sank 1336.7% in 2022 and soared 2156.77% in 2024, its largest moves.
• Over 5 years, Change in Receivables stood at -$19.4 million in 2022, then surged by 330.96% to $44.8 million in 2023, then surged by 180.61% to $125.7 million in 2024, then slumped by 101.86% to -$2.3 million in 2025, then jumped by 5124.62% to $117.6 million in 2026.
• The last three Change in Receivables figures came in at $117.6 million (Q2 2026), $75.3 million (Q1 2026), and -$2.3 million (Q4 2025), per Business Quant data.